Dr Emily Eaton

Dr Emily Eaton
Emily joined Sygnature in July 2012 as an in vitro Bioscientist and was appointed as Business Development Executive in November 2015, to facilitate further growth of Sygnature’s bioscience related-business. Emily was promoted to Business Development Manager in April 2017 and was made Business Development Director in August 2018.
Emily has seven years of small molecule drug discovery experience and has supported projects from proof of concept to candidate drug selection, across multiple therapeutic areas and target classes. Emily has a BSc (Hons.) in biochemistry and a PhD in telomere biology from the University of Nottingham.